

Supporting Information

**Hypoxia-Alleviated Sonodynamic Therapy based on Hybrid Protein
Oxygen Carrier to Enhance Tumor Inhibition**

Ting Yin^{1,2,‡}, Jia Yin^{2,‡}, Hui Ran^{1,2}, Yaguang Ren², Chengyu Lu¹, Lanlan Liu², Qingxia Shi^{1,2}, Yuzhi Qiu¹, Hong Pan^{2,} and Aiqing Ma^{1,2,*}*

¹Guangdong Key Laboratory for Research and Development of Natural Drugs, Key Laboratory for Nanomedicine, Guangdong Medical University, Dongguan 523808, PR China.

²Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, Shenzhen Engineering Laboratory of Nanomedicine and Nanoformulations, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen 518055, P.R. China.

*Corresponding Authors: H. Pan (hong.pan@siat.ac.cn) and A. Ma (maqandght@126.com)

‡ These authors contributed equally to this work.




Figure S1 DLS of MnPcS@HP NPs, suggesting the high uniform sizes of the NPs.




Figure S2 The mean size of the the MnPcS@HP NPs in 7 days in PBS solution.




Figure S3 The mean size of the the MnPcS@HP NPs in 7 days in FBS solution.




Figure S4 The release curve in PBS solution and PBS solution with 10 mM GSH.